Indo-Bangla Pharmaceuticals Limited (DSE: IBP)

Market Cap	1.07B
Revenue (ttm)	211.61M
Net Income (ttm)	-18.08M
Shares Out	116.21M
EPS (ttm)	-0.16
PE Ratio	n/a
Forward PE	n/a
Dividend	0.01 (0.11%)
Ex-Dividend Date	Dec 4, 2024

Volume	92,299
Open	n/a
Previous Close	9.10
Day's Range	9.00 - 9.30
52-Week Range	6.80 - 20.80
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 28, 2024

About DSE: IBP

Indo-Bangla Pharmaceuticals Limited manufactures and sells various medicines, medical preparations drugs, and chemicals in Bangladesh and internationally. Its principal products include analgesics and antipyretics, anthelmintic, anti-asthmatic, gastroprokinetic and antiemetic, antiprotozoal, non-hormone sex stimulant, non-steroidal, anti-inflammatory, steroids, and vitamins and minerals, as well as respiratory, cardiovascular, central nervous system, dermatology, and gastrointestinal categories. The company markets its products in various forms...

• Industry: Pharmaceutical Preparations
• Founded: 1954
• Employees: 194
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: IBP

Financial Performance

In 2023, IBP's revenue was 374.48 million, a decrease of -22.74% compared to the previous year's 484.68 million. Earnings were 8.41 million, a decrease of -66.60%.